Alamar Biosciences, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission, disclosing financial and operational information as a non-accelerated filer listed on NASDAQ:ALMR.

Key Highlights

  • Share count: As of July 31, 2026, the company had 69,392,766 shares of common stock, $0.0001 par value per share, outstanding.
  • Filer status: The company reported it is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
  • Ongoing losses: The company disclosed it "has incurred losses since inception" and expects to incur losses in the future.
  • Government funding dependency: The filing stated the business "is significantly dependent on researchers who rely heavily on government funding, including NIH grants."
  • Product focus: The company identified the ARGO HT instrument and related assays as central to its growth strategy.
  • Competitive environment: The filing noted that "the proteomics market is highly competitive."

Alamar Biosciences Q2 2026: Key Disclosures on Operations, Risks, and Capital

Alamar Biosciences, Inc. (NASDAQ:ALMR), headquartered at 47071 Bayside Parkway, Fremont, California 94538, submitted its Form 10-Q for the quarterly period ended June 30, 2026. According to the filing, the company operates in the proteomics market and its primary commercial product is the ARGO HT instrument, along with associated assays. The registrant holds Commission File Number 001-43235 and is incorporated in Delaware.

The filing disclosed several material risk factors associated with the company's business. Among them, the company stated it has incurred losses since inception and expects those losses to continue, noting uncertainty about whether it can "generate sufficient revenue to achieve and maintain cash flows from operating activities in excess of our capital investment requirements or to achieve and sustain profitability." The company also identified its limited operating history as a factor that makes evaluating future prospects difficult. The filing further noted that a significant portion of revenue depends on research and academic institutions and, by extension, on government funding sources such as NIH grants, with the company warning that "any reduction in, modification of the terms of, or delay in such funding could adversely affect our sales and financial performance."

On growth strategy, the filing indicated that successfully developing and introducing new assays for the ARGO HT instrument, as well as new versions of the instrument itself, is a condition for generating new revenue sources. The company also acknowledged it has been and may in the future be involved in legal proceedings and regulatory inquiries. Forward-looking statements contained in the report are the company's own and are subject to the cautionary language set out in the filing's Special Note Regarding Forward-Looking Statements.

What Was Disclosed

Alamar Biosciences filed its Q2 2026 quarterly report covering the period ended June 30, 2026, disclosing ongoing operating losses, reliance on government-funded research customers, competitive risks in the proteomics market, and 69,392,766 shares outstanding as of July 31, 2026.